|
|
|
|
See how two activation methods compare for clinical-scale gamma delta T cell production. Anti-CD3/anti-CD28 co-activation addresses a common manufacturing hurdle and improves lentiviral transduction efficiency, supporting scalable gamma delta T cell therapy.
|
|
|
|
|
TheraPEAK® T-VIVO® Cell Culture Medium uses only recombinant proteins, with no animal-derived components, to simplify CAR-T manufacturing. In testing, it supported stronger T-cell expansion than other commercially available media.
|
|
|
|
|
TheraPEAK® AmpliCell® Cytokines are lyophilized, animal-component-free, xeno-free recombinant proteins produced in human cell lines. That expression gives them the post-translational modifications characteristic of native human cytokines for ex vivo cell culture.
|
|
|
|
|
Efficient, scalable delivery of CRISPR/Cas9 is critical for gene and cell therapies, and electroporation leads non-viral clinical approaches. See how the 4D-Nucleofector™ LV Unit PRO enables robust, scalable T-cell gene editing.
|
|
|
|
|
|
|
A biodegradable, nanoparticle-based CD3/CD28 agonist activates T cells with less stress than bead formats. It supports expansion of PBMCs or enriched T cells over 7 to 14 days in serum-free conditions.
|
|
|
|
|
Accelerate your cell and gene therapy journey with integrated technologies, GMP expertise, and end-to-end solutions, from development through manufacturing, designed to help bring transformative therapies to patients faster.
|
|
|